Business profile & competitive position
The Cooper Companies, Inc. operates inside the Healthcare sector, specifically in the Medical – Instruments & Supplies industry. Its business is split into two global medical-device segments: CooperVision and CooperSurgical. CooperVision develops, manufactures, and markets single-use, two-week, and monthly contact lenses, including silicone hydrogel lenses, orthokeratology and scleral lenses, and myopia-management products such as the MiSight 1 day lens. CooperSurgical offers more than 600 products and services concentrated on fertility and women’s health, spanning gynecology, obstetrics, contraception, labor and delivery, IVF support, donor gametes, cryopreservation, cord-blood/tissue storage, and genomic services. Products are sold in over 130 countries, and the company states that its devices positively impact more than fifty million lives each year.
From a competitive-moat perspective, CooperVision’s regulatory positioning stands out: MiSight 1 day is approved by the FDA, China’s NMPA, and Japan’s MHLW to slow the progression of, and correct, myopia in age-appropriate children. That tri-regulatory status is not common and gives the product a defended first-mover advantage in a specialized growth niche. The company also maintains roughly 500 R&D employees across both segments, which supports ongoing product-line refreshes and geographic expansion.
The margin and return figures, however, tell a more nuanced story. A net margin of 13.5% is solid for a medical-device manufacturer, but ROE of only 6.9% is relatively modest for a company of this scale. That gap suggests the balance sheet carries meaningful capital—likely including past CooperSurgical acquisitions and goodwill—that has not yet converted into high equity returns. In other words, Cooper has built breadth and regulatory reach, but its capital efficiency indicates that the integrated women’s-health strategy is still being digested and that the overall moat is stronger on the CooperVision side than on a consolidated capital-return basis.
Financial posture
With a market capitalization of $11.8 billion and a trailing P/E of 21.1, Cooper sits at a valuation that is neither deep-value nor aggressively growth-premium by medical-device standards. The implied earnings yield is around 4.7%, which, combined with a beta of 0.82, points to a lower-volatility, cash-flow-oriented profile rather than a high-beta momentum name. Net margin at 13.5% supports the idea that the core contact-lens business is a steady, recurring-cash generator once patients are fitted into a disposable-lens regimen.
Yet the 6.9% ROE reinforces the same capital-efficiency caveat raised above: for every dollar of shareholders’ equity, Cooper is generating less than seven cents of annual profit. That can happen when an acquisitive strategy loads the balance sheet with intangibles or when a new platform such as CooperSurgical requires continued reinvestment before margins mature. At the current snapshot, the stock is $61.82, with an RSI of 62.5 and a 50-day exponential moving average of $60.74, meaning price is modestly above its near-term trend but not in an extreme technical condition.
Overall, the financial posture is best described as a mid-cap healthcare compounder with dependable margins but structurally modest equity returns and a valuation that prices in moderate, rather than explosive, growth.
Strategic priorities & outlook
The company’s most recent SEC 10-K filing outlines four clear operational priorities. First, CooperVision is focused on driving greater worldwide market penetration of recently introduced products and on expanding its presence in both existing and emerging markets. Second, CooperVision is increasing investment in distribution and packaging capabilities to support business growth and quality service. Third, the segment is investing to develop the myopia-management market by educating eye care practitioners, patients, and families. Fourth, CooperSurgical expects to continue investing in its business, including through strategic transactions, in order to expand its integrated solutions model within fertility and women’s health.
These priorities paint a unified picture: CooperVision is the engine of near-term organic growth through market-share gains, myopia awareness, and supply-chain execution, while CooperSurgical is the longer-dated, transaction-driven platform that the company is still assembling. Investors evaluating Cooper should keep an eye on whether distribution and packaging investments translate into margin stability, and whether CooperSurgical’s deal activity starts to produce clearer returns on equity.
Macro & geopolitical exposure
Because Cooper is classified as a Medical – Instruments & Supplies company, its exposures are tightly linked to medical-device fundamentals rather than consumer-discretionary cycles. Regulatory risk is front and center: products must clear the FDA, China’s NMPA, Japan’s MHLW, and other national bodies, and any delay or remediation can alter revenue timing. Pricing and reimbursement pressure also matter, particularly in women’s health, where hospital systems and insurers influence adoption.
With sales in over 130 countries, foreign-exchange movements are a real factor in reported results; a stronger U.S. dollar can compress overseas revenue translated back into dollars, while a weaker dollar provides a tailwind. Supply-chain exposure includes specialized polymers, silicone hydrogel inputs, packaging materials, and sterile manufacturing logistics, all of which can be affected by trade policy, tariffs, freight costs, or raw-material inflation. Demographic trends such as rising myopia prevalence globally and shifting fertility patterns create demand drivers, but birth-rate softness in certain regions could temper CooperSurgical growth faster than demographic bulls expect. Finally, medical-device litigation and product-liability allegations are recurring industry risks that can create headline-driven volatility independent of quarterly fundamentals.
Recent developments
In the final week of October 2026, Cooper attracted a cluster of securities-litigation headlines. On October 22, 2026, both The Rosen Law Firm and the Pomerantz Law Firm issued investor alerts regarding The Cooper Companies, Inc.; a second Rosen alert followed on October 23, and a third on October 25. These releases encouraged investors who had suffered losses to contact the firms and discussed potential securities-class-action investigations. The filings came from globenewswire.com, newsfilecorp.com, and prnewswire.com.
These announcements are preliminary investigations, not judgments or settlements, but they are relevant context for traders because they can increase headline risk, expand the stock’s options-implied volatility around filings, and color sentiment toward management disclosures and guidance credibility. For fundamental investors, the key question is whether any underlying allegations connect to real operational issues—such as inventory, margin, or acquisition integration—or whether the notices are driven mainly by share-price declines. Either way, they add a governance and litigation-risk premium to the equity that did not dominate the narrative in the prior quarter.
Earnings behavior & post-earnings drift
Cooper’s recent earnings track record is statistically clean but behaviorally complicated. Over the last eight reported quarters the company has beaten the market’s real expectation in every single quarter, a beat rate of 8/8, or 100%, with an average earnings surprise of 4.2%. That suggests operational forecasting has consistently outperformed the published consensus.
The post-earnings price action, however, does not follow the same straight line. The average 5-day price move after earnings across those eight quarters is -2.34%, classified as a down drift. This is an important discrepancy: even when the company beats, the stock does not reliably hold or extend its gains. During the most recent four reported quarters, the pattern is stark:
- On September 9, 2026, Cooper reported EPS of $1.15 against an estimate of $1.12, a 2.7% positive surprise, yet the stock fell 14.67% the next day and 13.97% over the following five sessions.
- On June 4, 2026, actual EPS of $1.21 beat the $1.10 estimate by 10.0%, and the stock responded with a next-day gain of 8.58% and a five-day gain of 8.85%.
- On March 5, 2026, EPS of $1.10 beat the $1.03 estimate by 6.8%, but the stock dropped 4.55% the next day and 10.82% over the next five sessions.
- On December 4, 2025, EPS of $1.15 beat the $1.11 estimate by 3.6%, producing a next-day gain of 5.67% and a five-day gain of 6.59%.
The takeaway is that the headline beat is only part of the story. Forward guidance, segment-margin commentary, CooperSurgical performance, currency impacts, and broader healthcare sentiment have likely driven the wide dispersion in post-earnings returns. The September 2026 beat is especially notable: a modest 2.7% EPS surprise coincided with a double-digit drawdown, which points to either a reset in forward expectations, a negative change in tone from management, or a repricing unrelated to the quarter’s headline number.
Looking ahead, Cooper is scheduled to report next on December 3, 2026, after the close, with a current consensus EPS estimate of $1.07.
Frequently Asked Questions
Why does Cooper beat earnings so often but still drift lower after some reports?
Cooper has beaten the market’s real expectation in all of the last eight quarters, with an average surprise of 4.2%. However, the average five-day post-earnings drift over that stretch is -2.34%, meaning guidance, segment-margin commentary, and forward sentiment have sometimes outweighed the headline beat. The September 2026 quarter is the clearest example: EPS exceeded estimates by 2.7%, yet the stock fell nearly 15% the next day.
What are the company’s main growth priorities?
According to its most recent 10-K, CooperVision is prioritizing new-product penetration, geographic expansion, distribution and packaging investment, and myopia-management education. CooperSurgical is focusing on continued investment and strategic transactions to build an integrated fertility and women’s health platform.
How should investors think about Cooper’s valuation and returns?
At a market cap of $11.8 billion and a P/E of 21.1, Cooper carries a moderate healthcare-device valuation. Its 13.5% net margin is healthy, but its 6.9% ROE is relatively low, suggesting that capital invested—especially in CooperSurgical—has not yet fully converted into strong shareholder returns.
For a deeper dive into how the sell side currently views Cooper’s risk-reward, readers should consult the full institutional verdict, which includes analyst rating distributions, recent estimate revisions, target ranges, and institutional ownership trends.
| Reported | Actual | Estimate | Surprise | 1D Move | 5D Move |
|---|---|---|---|---|---|
| 2026-09-09 | $1.15 | $1.12 | +2.7% | -14.67% | -13.97% |
| 2026-06-04 | $1.21 | $1.1 | +10% | +8.58% | +8.85% |
| 2026-03-05 | $1.1 | $1.03 | +6.8% | -4.55% | -10.82% |
| 2025-12-04 | $1.15 | $1.11 | +3.6% | +5.67% | +6.59% |
| 2025-08-27 | $1.1 | $1.07 | +2.8% | - | - |
| 2025-05-29 | $0.96 | $0.928 | +3.4% | - | - |
Previous COO editions
Get the institutional verdict on COO
Seven-seat 21-ERT council. Pre-print forecast signed before the earnings release. Post-print grade, published in public. Every verdict sealed with a cryptographic receipt.
Read the COO verdict at Gamma QCVerify authenticity
Every Gamma QC verdict is signed with a cryptographic receipt at issuance. Independently verify any published verdict at attest.gammaqc.com. This educational primer is content-only and not itself signed; the institutional verdict at the link above is.